» Articles » PMID: 2479703

Mapping of the Epstein-Barr Virus and C3dg Binding Sites to a Common Domain on Complement Receptor Type 2

Overview
Journal J Exp Med
Date 1989 Dec 1
PMID 2479703
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Complement receptor type 2 (CR2;CD21), a member of the superfamily of proteins containing short consensus repeats (SCRs), is the B cell receptor for both the gp350/220 envelope protein of Epstein-Barr virus (EBV), and for the C3dg protein of complement. By analysis of CR2 deletion mutants and chimeras formed with CR1 (CD35) we determined that of the 15 SCRs in CR2, the NH2-terminal two SCRs are necessary and sufficient to bind both gp350/220 and C3dg with affinities equivalent to those of the wild-type receptor. The epitope for OKB-7, a mAb that blocks binding of both EBV and C3dg and shares with these ligands B cell-activating capabilities, also requires both SCR-1 and SCR-2, whereas mAbs lacking these functions bind to other SCRs. Thus, EBV, a polyclonal activator of B cells, has selected a site that is proximate or identical to the natural ligand binding site in CR2, perhaps reflecting the relative immutability of that site as well as its signal transducing function.

Citing Articles

The fixation of complement protein pairs to CR2 isoforms.

Barile G Biochem Biophys Rep. 2024; 38:101657.

PMID: 38371315 PMC: 10869749. DOI: 10.1016/j.bbrep.2024.101657.


Structural biology of complement receptors.

Santos-Lopez J, de la Paz K, Fernandez F, Vega M Front Immunol. 2023; 14:1239146.

PMID: 37753090 PMC: 10518620. DOI: 10.3389/fimmu.2023.1239146.


Tree Shrew Is a Suitable Animal Model for the Study of Epstein Barr Virus.

Xia W, Chen H, Feng Y, Shi N, Huang Z, Feng Q Front Immunol. 2022; 12:789604.

PMID: 35111158 PMC: 8801525. DOI: 10.3389/fimmu.2021.789604.


Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.

Soldan S, Su C, Lamontagne R, Grams N, Lu F, Zhang Y PLoS Pathog. 2021; 17(6):e1009618.

PMID: 34106998 PMC: 8216538. DOI: 10.1371/journal.ppat.1009618.


Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration.

Annamalai B, Parsons N, Nicholson C, Joseph K, Coughlin B, Yang X Exp Eye Res. 2021; 207:108583.

PMID: 33878326 PMC: 8504679. DOI: 10.1016/j.exer.2021.108583.


References
1.
Dolyniuk M, Pritchett R, Kieff E . Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol. 1976; 17(3):935-49. PMC: 515494. DOI: 10.1128/JVI.17.3.935-949.1976. View

2.
Toneguzzo F, Glynn S, Levi E, Mjolsness S, Hayday A . Use of a chemically modified T7 DNA polymerase for manual and automated sequencing of supercoiled DNA. Biotechniques. 1988; 6(5):460-9. View

3.
Hoffman G, Lazarowitz S, Hayward S . Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980; 77(5):2979-83. PMC: 349530. DOI: 10.1073/pnas.77.5.2979. View

4.
Harada S, Sakamoto K, Seeley J, LINDSTEN T, Bechtold T, Yetz J . Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects. J Immunol. 1982; 129(6):2532-5. View

5.
Dahlback B, Smith C, MULLER-EBERHARD H . Visualization of human C4b-binding protein and its complexes with vitamin K-dependent protein S and complement protein C4b. Proc Natl Acad Sci U S A. 1983; 80(11):3461-5. PMC: 394064. DOI: 10.1073/pnas.80.11.3461. View